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Only two sweeping improvements have occurred in clinical organ 
transplantation since 1962, each associated with the advent of a more 
effective baseline immunosuppressant.39 The first was replacement of 
azathioprine with CYclosporine as the baseline immunosuppressant 
(1979-1980); the second was substitution of tacrolimus (1989-1990); how-
ever, what was actually being accomplished with these drugs remained 
enigmatic until only 5.5 years ago and is still incompletely worked 
out. Nevertheless, it now can be suggested that the riddle of allograft 
acceptance has been solved in principle, if not in detail.35 With this fresh 
insight, it may be possible to map effective strategies that will make 
xenotransplantation feasible. 
INITIAL INSIGHT 
Enduring interest in the clinical applications of transplantation usu-
ally is dated to the first demonstration of "acquired tolerance" to skin 
grafts in mice that had been infused with allogeneic splenocytes or bone 
marrow in utero or just after birth.2, 3 This so-called "neonatal tolerance" 
was strongly associated with donor hematopoietic chimerism and was 
Supported in part by research grants from the Veterans Administration and Project 
Grant No. DK-29961 from the National Institutes of Health, Bethesda, Maryland. 
From the Thomas E. Starzl Transplantation Institute (TES, ASR, NM, AJD, AT, JJF) and the 
University of Pittsburgh School of Medicine (TES, NM, AJD, AT, JJF), Pittsburgh, 
Pennsylvania 
SURGICAL CLINICS OF NORTH AMERICA 
VOLU\.fE 79 • NUMBER 1· FEBRUARY 1999 191 
192 STARZL et al 
generally construed as replacement of the native immune system before 
it was sufficiently mature to reject the hematopoietic grafts obtained 
from adult donors. 
Bone marrow transplantation after cytoablation of the adult recipi-
ent with total body irradiation or myelotoxic drugs was, in essence, a 
simulation of the neonatal modePl Ironically, bone marrow transplanta-
tion was not accomplished clinically until 1968, and then only with the 
use of human leukocyte antigen-matched donors49 9 years after the first 
successful organ transplantation in humans24; however, because of its 
strong association with tolerance, attempts to produce donor leukocyte 
chimerism in preparation for, or at the same time as, tissue and organ 
transplantation dominated surgical research until the early 1960s.25 
These efforts to combine adjunct donor bone marrow infusion with 
organ transplantation were largely abandoned by the end of 1963. The 
loss of interest stemmed from evidence suggesting that kidney allografts 
were inherently tolerogenic, seemingly eliminating the need for the 
dangerous cytoablation that was assumed to be a prerequisite for donor 
leukocyte engraftment. The concept of organ tolerogenicity was encapsu-
lated in the title of the article "The reversal of rejection in human renal 
homografts with subsequent development of homograft tolerance,"41 
in which the combined use of azathioprine and dose-maneuverable 
prednisone was described for the first time. 
The use of "tolerance" to characterize the progressively diminishing 
need for maintenance immunosuppression after the early postoperative 
period of these patients4! was harshly criticized at the time, and subse-
quently; however, the term was apposite. Although none of the pioneer 
patients were weaned from immunosuppression until much later,37 long-
term drug-free allograft acceptance already had been recorded by 1964 
in a few mongrel canine kidney recipients treated for a year post-
transplantation with 6-mercaptopurine or its analogue, azathioprine. 
This was accomplished with even greater regularity after canine liver 
transplantation following only 4 months of similar immunosuppres-
sion.33 
Soon thereafter, permanent liver graft acceptance without any treat-
ment at all was described in outbred pigs, many of which passed 
through spontaneously resolving rejection crises. Thus, it was obvious 
30 years ago that chemotherapeutic immunosuppression was permitting, 
rather than causing, a fundamental change in the host, the graft, or 
probably both.33, 34, 37 
Finally, it was demonstrated, first in pigs5 and then in rodents,54 that 
the tolerance self-induced by a liver allograft also extended to other 
organs transplanted simultaneously or later from the same donor (donor-
specific nonreactivity; tolerance). Although these observations were most 
readily exemplified with liver transplant models, "hepatic tolerogeni-
city" was only an extreme manifestation of a property that is variably 
shared by all tissues and organs.2S, 36-38 Eventually, it was shown that the 
unusual tolerogenicity of the liver was caused by its large content 
compared with other organ allografts of bone marrow-derived donor 
------_ .. __ ._ .. __ ._-------------
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Figure 1. The explanation for the variable ability of different organ allografts to induce 
acceptance and ultimately tolerance. The authors postulate that the dendritic leukocyte is 
the single most important (see text), although not the only, tolerogenic cell by virtue of its 
role in antigen presentation and clonal activation, which leads to exhaustion/deletion. 
Although the intestine is leukocyte-rich, the total number of donor leukocytes in this hollow 
organ is less than in the liver; in addition, the high percentage of mature T cells makes the 
bowel allograft more GVHD prone than other organs. Stars represent chimeric donor cells 
in the recipient. (From Starzl TE, Demetris AJ, Trucco M, et al: Cell migration and chimerism 
after whole-organ transplantation: The basis of graft acceptance. Hepatology 17: 1127-1152, 
1993; with permission.) 
leukocytes (Fig. 1).25,36-38 These "passenger leukocytes" make up most of 
the nonparenchymal cells (NPCs) of all tissues and organs. 
THE ENEMY: PASSENGER LEUKOCYTES 
Because of their strong immunogenicity, passenger leukocytes (par-
ticularly mature dendritic cells44) have long been known to provide the 
principal stimulus leading to organ rejection. 20, 45 In addition to the 
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recipient immune reaction induced within the allografts by the donor 
hematopoietic cells,lO, 11 it has been recognized for more than 15 years 
that these donor leukocytes induce widespread immune activation after 
their hematogenous migration from the transplanted organ to host 
lymphoid organs. 10, 18, 27 
It also was demonstrated as early as 196916 that the migratory cells 
following successful transplantation of hepatic allografts were replaced 
in the organ by an influx of recipient cells of the same lineages, a 
phenomenon that was wrongly thought for nearly 2 decades to be 
unique to the liver, In addition, destruction by the recipient immune 
system of the highly immunogenic donor leukocytes, either within the 
transplanted organ or after their peripheral migration, was incorrectly 
assumed to be a prerequisite for successful organ transplantation. This 
latter assumption, which already had become dogma by 1963, was not 
challenged for nearly 3 decades. 
THE DISCOVERY OF DONOR LEUKOCYTE 
CHIMERISM 
As a result of these conceptual errors, numerous chimerism-exclu-
sionary theories were elaborated between 1962 and 1992 to explain organ 
allograft "acceptance" by different mechanisms than those responsible 
for neonatal tolerance or for the tolerance seen after clinical bone marrow 
transplantationY When peripheralized donor leukocytes were discov-
ered in 1992 to be present in small numbers (microchimerism) in host 
lymphoid and nonlymphoid areas as many as 30 years after organ 
transplantation/h , 38 the authors suggested that the different forms of 
acquired tolerance, including organ allograft acceptance, were all varia-
tions on the same theme (Fig. 2). As a practical matter, the implication 
was that "clinical success (after transplantation)-tolerance or graft 
acceptance-means that a characteristic lymphoid and dendritic cell 
[DC] chimerism has been introduced, which may be stable either without 
further treatment or only when further immunosuppression is provided; 
an unstable graft and its migrated cells may either be rejected or cause 
graft-versus-host disease.36 
MECHANISMS ASSOCIATED WITH CHIMERISM 
Clonal Exhaustion or Depletion 
In the first few days after organ transplantation, multilineage bone 
marrow-derived donor ("passenger") leukocytes, which include pluri-
potent stem cells25,26 and dendritic cells,8, 9, 25, 30, 36, 38 constitute 1% to 20% 
of the host circulating mononuclear cells, depending on the kind of 
allograft (i.e., highest with liver and intestine, lowest with heart or 
kidney).2s,38 Although their primary migration is to lymphoid organs,8, 
Freemartin Cattle 
(1 
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Figure 2. The continuum from observations of natural chimerism in Freemartin cattle to 
the present time. Chimerism was incorrectly discounted as a factor in organ allograft 
acceptance from about 1960 until the discovery in 1992 of microchimerism in organ 
recipients. (From Starzl TE, Demetris AJ, Murase N, et al: The lost chord: Microchimerism. 
Immunol Today 17:577-584,1996; with permission.) 
9,30 beginning in approximately 2 weeks, small numbers of donor leuko-
cytes can be found increasingly in other tissues; by 3 months, they are 
mostly in nonlymphoid sites (e.g., skin and native heart).35, 36, 38, 48 
Even with the limited information available in 1992, it was possible 
to suggest that organ allograft acceptance involved "[acute] responses of 
co-existing donor and recipient immune cells, each to the other, causing 
reciprocal clonal expansion, followed by peripheral clonal deletion."36 The 
characteristic cycle of immunologic crisis and resolution, first observed in 
drug-immunosuppressed kidney recipients and most practically moni-
tored by serial changes in allograft function,41 was not simply a host-
versus-graft reaction (rejection). It was the product of the dual immune 
reaction: host-versus-graft and graft-versus-host (Fig. 3).25,35-38 
The mutually canceling effect of the donor and recipient cell popula-
tions as both underwent clonal exhaustion and depletion explained the 
rarity of graft-versus-host disease following the engraftment in noncy-
toablated recipients of immunologically active organs, such as the intes-
tine and liver. 36, 38 Disruption of the leukocyte interaction with the host 
cytoablation used to prepare bone marrow recipients (Fig. 4) but not the 
recipients of whole organs (Fig. 4) obviously was responsible for the 
differences between bone marrow and organ transplantation (Table 1), 
including absolute dependence on human leukocyte antigen matching 
to avoid graft-versus-host disease in the first instance but not the second. 
In the framework of the double immune reaction, treatment failure 
for immunologic reasons after essentially all transplantation procedures 
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Figure 3. Contemporaneous host-versus-graft (HVG) and graft-versus-host (GVH) reac-
tions in the two-way paradigm as applied to organ transplantation. Following the initial 
interaction, the evolution of nonreactivity of each leukocyte population to the other is seen 
as a predominantly low-grade stimulatory state that may wax and wane, rather than a state 
of absolute or irreversible clonal deletion. After bone marrow transplantation to a recipient 
who has undergone cytoablation, the conditions are a mirror image. 
can be defined as uncontrollable ascendancy of one of the interactive 
arms (Fig. 3) or sometimes both together. The strongest reaction in organ 
recipients usually is host-versus-graft (rejection) (Fig. 3). In bone marrow 
recipients, it usually is graft-versus-host. 
Immune Indifference 
In addition to clonal exhaustion and depletion, it was proposed in 
1992 that "acceptance" of transplanted organs was facilitated by the in 
situ depletion of leukocytes post-transplantation and a consequent loss 
of allograft immunogenicity.36,38 This effect of leukocyte depletion has 
been demonstrated in many different experimental models.17, 20, 45, ~S Thus, 
with successful organ engraftment, three progressive changes presum-
ably take place at about the same time: (1) diminished immunogenicity 
of the allograft, allowing the host immune system to view it with 
progressive indifference; (2) clone-specific host exhaustion and depletion 
of host-versus-graft reactivity; and (3) reciprocal passenger leukocyte 
exhaustion or depletion of graft-versus-host specificity. A stable allograft 
emerging from this triple process eventually may come to resemble an 
immunologically neglected infection.35 
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Figure 4. Two-way paradigm in which transplantation is seen as bidirectional and mutually 
canceling immune reactions that are (A) predominantly HVG with whole organ grafts and 
(8) frequently GVH with bone marrow grafts. 
THE MICROCHIMERISM CONTROVERSY 
Skepticism about the significance of microchimerism4,53 has been 
based on (1) the inconsistency with which donor leukocytes can be 
found in blood or tissue samples from recipients of long-surviving organ 
allografts, (2) the development of acute or chronic rejection despite 
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Table 1. DIFFERENCES BETWEEN CONVENTIONAL BONE MARROW AND ORGAN 
TRANSPLANTATION 
Bone Marrow 
Yes 
Critical 
GVHD 
Common 
Tolerance 
Organ 
<- Recipient cytoablation* -c* No 
<- MHC compatibility ~ Not critical 
<- Principal complication ---> Rejection 
<- Drug-free state ---> Rare 
<- Term for success ---> "Acccptancc"t 
* All differences derive from this therapeutic step, which, in effect, establishes an unopposed graft-
versus-host reaction in the bone marrow recipient whose countervailing immune reaction is eliminilted. 
tOr "operational tolerance." 
MHC, major histocompatibility complex; GVHD, graft-versus-host disease. 
demonstrable chimerism, and (3) the inability to use microchimerism 
to guide post-transplant weaning of immunosuppression, All of these 
observations can be readily fitted into the concept of the various chimeric 
states, providing the chimerism is coupled with the degree of altered 
immunogenicity of the allograft and that the extent to which reciprocal 
clonal exhaustion or depletion has occurred is factored in.42 These param-
eters vary with time and are subject to a common governance. 
GOVERNANCE OF MECHANISMS 
One of the authors (TES) and Zinkemagel of Zurich35 have proposed 
that the immunologic response or nonresponse against infections or 
tumors, and under the conditions of clinical transplantation, are gov-
erned primarily by the migration and localization of antigen. In this 
view, immune reactivity depends on migration of antigen to organized 
lymphoid tissue and can be viewed as "a balance between potentially 
reactive lymphocytes versus the qualities, quantity, kinetics, and distri-
bution of the antigen (foreign or self) within the host.''35 In this context, 
nonreactivity can be the consequence of immune activation, followed by 
clonal deletion. Nonreactivity also may occur by default if the antigen 
never reaches lymphoid organs or is secondarily sequestered in non-
lymphoid sites (immune indifference).35 
Thus, donor leukocyte chimerism is a prerequisite for, but not syn-
onymous with nor a consequence of, the evolution of allograft 
tolerance. J5 -38,42 Although the association of chimerism with organ allo-
graft acceptance was discounted for 30 years,37 the principle of chime-
rism-linked organ allograft acceptance is no different than in the rodent 
neonatai,2' 3 cytoablation-dependent,21 parabiosis-induced,22 and more 
complicated "mixed chimerism" tolerance models15, 32, 50 (Fig. 2). The 
theme came full-circle back to the observations by Owen28 more than 50 
years ago of natural reciprocal tolerance to allogeneic blood cells and 
skin grafts in nonidentical (Freemartin) twin calves whose circulations 
were joined in fetal life as the result of placental fusion (Fig. 2). 
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INFECTIOUS AND TRANSPLANT ANALOGIES 
The barrier to successful transplantation of allografts and xenografts 
is the result of a survival-driven coevolution of the host immune system 
with environmental microorganisms. 55, 57 The immune response is similar 
against lethal cytopathic pathogens and the less dangerous noncyto-
pathic varieties, but with distinct and variable consequences. 
Noncytopathic Pathogens and Allografts 
In a prophetic early review, Lawrence19 compared the rejection of 
primary allografts with infections associated with delayed hypersensitiv-
ity (e.g., tuberculosis). The MHC-restricted mechanisms of this kind of 
immune response were unknown at the time. Once they were recog-
nized, it was obvious that immune rejection of infected cells or tumors 
was the physiologic equivalent of allograft rejection.56 
Because these largely intracellular infectious agents may be noninju-
rious, a high priority is avoidance of excessive immunologic tissue 
damage. Otherwise, immune destruction of widely disseminated patho-
gens (e.g., hepatitis B or C virus) can kill or disable the host.55,57 To 
prevent this, means exist that can temper or terminate the immune 
response. These are the same mechanisms (i.e., clonal exhaustion or 
depletion and immune indifference) that have been exploited for success-
ful allotransplantation (see previous discussion). 
Cytopathic Antigens and Xenografts 
In contrast to the graded and highly targeted response to noncyto-
pathic pathogens, the full resources, first of the innate and then of the 
specific (adaptive) immune system, are urgently mobilized to quickly 
and completely eliminate the damaging parasites without regard for 
destruction of host tissues by immunologic mechanisms.35, 55, 57, 58 The 
first line of defense is dominated by interferons, macrophages, gamma-
delta T cells, and "natural" killer cells. In addition, B cells whose recep-
tors are maximally cross-linked may be activated directly without T-
cell help. 
The antigenic signal issued by an infectious invader to B cells comes 
from its densely arranged and ordered repetitive epitopes, sometimes 
aided by lipopolysaccharides or by other unknown means.55 In addition, 
nonspecific or less-specific effector mechanisms, such as complement, 
interleukins, and phagocytes, are promptly involved. The specific T-cell 
and B-cell immune responses then usually control cytopathic infections 
definitively. 
These are the same mechanisms, predominantly those of innate 
immunity, that are responsible for the hyperacute rejection of discordant 
xenografts, and of allografts transplanted to ABO-incompatible or highly 
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sensitized recipients.43 The best-characterized signal on the cells of dis-
cordant xenografts is the terminal residue Gal-a-(1,3)-Ga1.6,13 This anti-
gen is chemically similar to ABO antigens and is found on numerous 
bacteria, protozoa, and virusesY 
Human complement regulatory proteins have been transfected into 
pigs?' 23, 52 in an effort to prevent clinical hyperacute xenograft rejection. 
This results only in temporary delay of xenograft destruction,], 1~ The 
reason is that the other mechanisms of innate immunity promptly cause 
inexorable rejection. Thus, additional genetic manipulation is required, 
whereby antigens are eliminated or equivalent human genes are intro-
duced. The realistic objective is not to completely avoid the cell-mediated 
rejection of adaptive immunity but rather to change the epitope pattern 
to one that will be recognized by the immune system as a noncytopathic 
(i.e., allo-) antigen. 
CHANGING THE XENOGRAFT PROFILE 
Gene-knockout procedures have not yet been done in the pig; how-
ever, using molecular technologies, some of which already have been 
shown to be applicable in pigs, Osman and colleagues29 in Australia 
have been able to reduce cell surface expression of the Gal-a-Gal gene 
product in cultured African green monkey fibroblasts (so-called "COS 
cells") to negligible levels. As a first step in these staged experiments, 
the COS cells, which normally do not express the Gal-ex-Gal epitope, 
were transfected with the Gal eDNA. Now presenting a Gal-ex-Gal target, 
the transfected COS cells were vigorously lysed in human serum (Fig. 5). 
gene product 
Transfected COS* Cell 
Gal-ex-Gal 
Transgene 
u··· .. ·· .: . : ....... . 
'.' .. ' ;<: .. ::.' ::K:K::~:: '  
:', •••• • ••••••••• :: -- p' 
·····~/i;: 
cz~ 
Lysed by human serum 
Figure 5. COS cells are lysed by human serum after their transfection with the Gal-a (1,3) 
Gal gene (see text). *African green monkey fibroblast (From Starzl TE, Rao AS, Murase N, 
et al: Will xenotransplantation ever be feasible? J Am Coli Surg 186:383-387, 1998; with 
permission. ) 
Added transfection 
of a-galactosidase ~ 
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Reduced lysis 
by human serum 
Figure 6_ Insertion of a-galactosidase gene diminishes but does not eliminate the lysis 
shown in Figure 5. (From Starzl TE, Rao AS, Murase N, et al: Will xenotransplantation 
ever be feasible? J Am Coli Surg 186:383-387, 1998; with permission.) 
The anti-Gal lysis was reduced but not eliminated by transfection 
of the altered COS cells with human a-galactosidase, which cleaves off 
a-linked galactosyl residues of the target epitope (Fig. 6). Because this 
exposes subterminal saccharides (i.e., N-acetyl lactosamine) to which 
there also are "natural" human antibodies, lysis is only reduced; how-
ever, the additional insertion of an a-l,2-fucosyl transferase gene resulted 
in the substitution of Gal-a-Gal with the nonimmunogenic H substance 
(i.e., the universally tolerated 0 blood group antigen). Thus, the double 
transfection (galactosidase plus fucosyl transferase) completely elimi-
nated complement-mediated lysis of the COS cells (Fig. 7). 
The a-galactosidase gene has not yet been transfected in pigs, but 
this has been accomplished with the a-fucosyl transferase gene by Logan 
and associates of the Nextran Corporation in collaboration with Sharma 
and colleagues at Duke University.31 Stable double transfection in pigs 
may be a realizable objective. 
SUMMARY 
In both transplant and infectious circumstances, the immune re-
sponse is governed by migration and localization of the antigen. If the 
antigenic epitopes of transgenic xenografts are sufficiently altered to 
avoid evoking the destructive force of innate immunity, the mechanisms 
of engraftment should be the same as those that permit the chimerism-
dependent immunologic confrontation and resolution that is the basis of 
allograft acceptance. 
In addition to "humanizing" the epitopes, one of the unanswered 
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Figure 7. Additional insertion of the a:-1 ,2-fucosyl transferase gene converts the xenogeneic 
Gal-a: (1,3) Gal antigen to the H (0, or universal donor) antigen and eliminates lysis (see 
text). (From Starzl TE, Rao AS, Murase N, et al: Will xenotransplantation ever be feasible? 
J Am Coli Surg 186:383-387, 1998; with permission.) 
questions is whether the species restriction of complement described in 
1994 by Valdivia and colleagues51 also necessitates the introduction of 
human complement regulatory genes in animal donors. Because the 
liver is the principal or sole source of most complement components,41,51 
the complement quickly is transformed to that of the donor after hepatic 
transplantation. Thus, the need for complementary regulatory transgenes 
may vary according to the kind of xenograft used, 
Much evidence shows that physiologically important peptides pro-
duced by xenografts (e.g" insulin, clottIng factors, and enzymes) are 
incorporated into the metabolic machinery of the recipient body.4'l To the 
extent that this is not true, xenotransplantation could result in the 
production of diseases that are analogous to inborn errors of metabolism. 
In the climate of pessimism that followed the failures of baboon to 
human liver xenotransplantation in 1992-1993,40,43 it seemed inconceiv-
able that the use of even more discordant donors, such as the pig, could 
ever be seriously entertained; however, this preceded insight into the 
xenogeneic and allogeneic barriers that has brought transplantation in-
fectious immunity to common ground.35 With this new insight and the 
increasing ease of producing transgenic donors, the goal of clinical 
xenotransplantation may not be so distant. 
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